USPTO serial 97828693
MODAGIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 24, 2024
- Examiner
- SMITH, BRENDAN K
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MODAGIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Wendelsheim, DE
Wendelsheim, DE
Wendelsheim, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ralph G. Fischer
Ralph G. Fischer Buchanan Ingersoll & Rooney PC501 Grant StreetSuite 200Pittsburgh, PA 15219Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for human medical purposes in the nature of pharmaceutical preparations for the use in the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Medicines for veterinary purposes for treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Pharmaceuticals and natural remedies, namely, natural remedy preparations for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Medicines for the treatment of Alzheimer's disease; Medicines for the treatment of neurodegenerative diseases; Medicines for the treatment of cardiovascular and cerebrovascular diseases; Chemical-pharmaceutical preparations for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Chemical reagents for medical or veterinary purposes; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations and materials for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for medical purposes; Injectable pharmaceuticals for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Medicinal preparations and substances for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Agents against Parkinson's disease, namely, pharmaceutical agents for the treatment of Parkinson's disease; Pharmaceutical medicines in the nature of pharmaceutical preparations for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Pharmaceutical products for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Pharmaceutical preparations for human use for the treatment of neurodegenerative diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, central nervous system, Parkinson's disease; Pharmaceutical preparations for the treatment of Parkinson's disease; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of neurodegenerative diseases; Pharmaceutical preparations for the treatment of cerebral disease; Pharmaceutical preparations for the treatment of central nervous system diseases | ACTIVE | — |
| 042 | Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consultancy relating to pharmaceutical research and development; Biological research, clinical research and medical research in the field of pharmaceuticals; Medical research laboratory services; Conducting technical tests on pharmaceuticals; Conducting analysis of human serum for medical research; Conducting analysis of human tissues for medical research; Development of pharmaceutical preparations and medicines; Pharmaceutical products development; Research and development of vaccines and medicines; Providing scientific information in the field of medical disorders and their treatment; Research in the field of pharmacogenetics; Research relating to pharmaceuticals; Research and development in the field of pharmacy and biotechnology; Clinical research in the field of pharmaceuticals; Laboratory research services relating to pharmaceuticals; Medical research; Medical and pharmacological research services; Pharmaceutical drug development services; Pharmaceutical research services; Pharmaceutical research and development; Quality testing for pharmaceutical products; Scientific research in the field of pharmacy; Scientific research and development | ACTIVE | — |
| 044 | Medication counseling; Providing information to patients in the field of administering medications; Providing medical information relating to pharmaceutical products; Providing information relating to the treatment of degenerative diseases; Providing information relating to medical services; Medical advisory services relating to degenerative diseases; Medical consultancy and medical information services relating to pharmaceutical products; Medical consultancy and medical information services relating to pharmaceutical products provided via the Internet; Medical consultancy and medical information services relating to medical products; Medical consultancy services relating to medicines; Medical services; Medical services for the treatment of Alzheimer's disease; Pharmaceutical compounding services; Preparation and administration of medicines being medical services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MODAG GmbH
- Other trademarks owned by MODAG GmbH
- Other trademarks owned by MODAG GmbH
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MODAGIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 24, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 24, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 22, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 22, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 2, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 13, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 11, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 11, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 10, 2024 | ALIE | ASSIGNED TO LIE | — |
| Mar 25, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 25, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 25, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 23, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 7, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 6, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 28, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 11, 2023 | NWAP | NEW APPLICATION ENTERED | — |